Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 297

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 297
---
 neurodegenerative diseases” was granted by the European Patent Office and the mention of grant was published in the European bulletin on July 24, 2024 and the European patent will be granted under number 3 433 381. The patent, which is set to expire in March 2037, claims the use of methods developed by DiamiR for early diagnosis of amyotrophic lateral sclerosis (ALS). DiamiR’s team has developed a substantial know-how in extracting, detecting, and analyzing miRNAs. All statistical analyses are performed with the proprietary software developed by DiamiR, which is currently maintained as trade secret. Data analysis performed with DiamiR’s software will become an integral part of the tests developed by DiamiR. 181 DiamiR also plans on seeking trademark protection for commercially valuable products it develops. At the date of this proxy statement/prospectus U.S. Federal trademark registrations for the marks CogniMIR ®and DiamiR ®have been issued by the USPTO. Market Size and Competition US market opportunity for CogniMIR ®in selection of early-stage patients for clinical trials— the following key market statistics are relevant for assessment of the overall size of this opportunity are compiled by the Alzheimer’s Association (alz.org):

| ● | The population of Americans age 65 and older is projected 
 to grow from 58 million in 2021 to 88 million by 2050.    |

| ● | The percentage of people with Alzheimer’s dementia increases                                                 
 with age: from 5.1% of people age 65 to 74 up to 33.4% of people age 85 and older have Alzheimer’s dementia. |

| ● | Almost 2/3 of American with AD are women. Of the 6.7 million                                                      
 people age 65 and older with Alzheimer’s dementia in the United States, 4.1 million are women and 2.6 million are 
 men. This represents 12% of women and 9% of men age 65 and older in the United States.                            |

| ● | By 2025, the number of people age 65 and older with Alzheimer’s                                             
 dementia is projected to reach 7.2 million — an 11% increase from the 6.7 million age 65 and older affected 
 in 2023.                                                                                                    |

182

| ● | The figures in the table above only reflect information pertaining 
 to the United States.                                              |